Benzinga | Jul 23, 2020 04:13PM EDT

UPDATE: eHealth Raises FY20 Adj. EPS Guidance From $3.41-$3.90 To $3.83-$4.32 vs $3.82 Est., Sales Guidance From $600M-$640M To $630M-$670M vs $639.48M Est.

The following is the updated guidance for the full year ending December 31, 2020:

* Total revenue is expected to be in the range of $630.0 million to $670.0 million, compared to the previous guidance of $600.0 million to $640.0 million. Revenue from the Medicare segment is expected to be in the range of $583.0 million to $619.0 million, compared to the previous guidance of $553.0 million to $589.0 million. Revenue from the Individual, Family and Small Business segment is expected to be in the range of $47.0 million to $51.0 million, consistent with the previous guidance.

* GAAP net income is expected to be in the range of $79.0 million to $94.0 million, compared to the previous guidance of $70.0 million to $85.0 million.

* Adjusted EBITDA(a) is expected to be in the range of $140.0 million to $155.0 million, compared to the previous guidance of $125.0 million to $140.0 million.

* Medicare segment profit(b) is expected to be in the range of $176.0 million to $193.0 million, compared to the previous guidance of $157.0 million to $174.0 million. Individual, Family and Small Business segment profit is expected to be in the range of $17.0 million to $18.0 million, consistent with the previous guidance.

* Corporate(c) shared service expenses, excluding stock-based compensation and depreciation and amortization, is expected to be in the range of $53.0 million to $56.0 million, compared to the previous guidance of $49.0 million to $52.0 million.

* Cash used in operations is expected to be in the range of $85.0 million to $95.0 million, compared to the previous guidance of $61.0 million to $64.0 million, and cash used for capital expenditures is expected to be in the range of $23.0 million to $25.0 million, compared to the previous guidance of $18.0 million to $20.0 million.

* GAAP net income per diluted share is expected to be in the range of $2.91 to $3.47, compared to the previous guidance of $2.55 to $3.10 per share.

* Non-GAAP net income per diluted share(d) is expected to be in the range of $3.83 to $4.32, compared to the previous guidance of $3.41 to $3.90 per share.